Scientific Committee on Epigenetics and Genomics
Committee Roster
Chair
Dinesh
聽S.聽Rao,聽MD, PhD
聽('24)
Vice Chair
Megan
聽E.聽McNerney,聽MD, PhD
聽('24)
Appointed Members
Marjorie聽Brand,聽PhD
聽('24)
Francine
聽E.聽Garrett-Bakelman,聽MD, PhD
聽('25)
Dan Avi
聽A.聽Landau,聽MD, PhD
聽('24)
Daniel聽Lipka,聽MD
聽('27)
Vikram
聽R.聽Paralkar,聽MD
聽('24)
Justin聽Taylor,聽MD
聽('27)
Zuzana聽Tothova,聽MD, PhD
聽('27)
Nan聽Zhu,聽PhD
聽('27)
Staff Liaison
础濒颈肠别听碍耻补产补苍,听惭厂
Committee Mandate
The ASH Scientific Committee on Epigenetics and Genomics will focus on scientific and clinical studies aimed at understanding the molecular mechanisms by which epigenetic and genomic alterations regulate normal and malignant blood cell development and function. Epigenetics encapsulates mechanisms which regulate DNA transcription, repair, and replication other than DNA sequence variants. This includes covalent cytosine modifications, including DNA methylation and hydroxymethylation, histone modifications, and non-coding RNAs. Genomics captures alterations made in the DNA sequence during development, such as seen in immune receptors, or mutations from oncogenic transformation. This Committee would also cover the mechanisms behind these epigenetic and genomic alterations, not just their outcomes.The strength of the Committee is that it can integrate the epigenetic and genetic sequence alterations that both mediate normal development and lead to malignancy. Thus, genetic changes that mediate epigenetic marks, and vice versa, can be presented here. The Committee will also seek to highlight clinical and translational studies that describe the preclinical and clinical development of agents that alter epigenetic/genomic marks and studies that improve our understanding of how epigenetically- or genomically-targeted therapies improve outcomes for patients with hematopoietic malignancies.
...